skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Transcatheter treatment of native aortic valve regurgitation: Results from an international registry using the transfemoral ACURATE neo valve

International journal of cardiology. Heart & vasculature, 2020-04, Vol.27, p.100480-100480, Article 100480 [Peer Reviewed Journal]

2020 The Authors ;2020 The Authors. ;2020 The Authors 2020 ;ISSN: 2352-9067 ;EISSN: 2352-9067 ;DOI: 10.1016/j.ijcha.2020.100480 ;PMID: 32083165

Full text available

Citations Cited by
  • Title:
    Transcatheter treatment of native aortic valve regurgitation: Results from an international registry using the transfemoral ACURATE neo valve
  • Author: Purita, Paola Angela Maria ; Tahoces, Luisa Salido ; Fraccaro, Chiara ; Nai Fovino, Luca ; Kim, Won-Keun ; Espada-Guerreiro, Cláudio ; De Backer, Ole ; Seiffert, Morritz ; Nombela-Franco, Luis ; Gomez, Raul Moreno ; Mangieri, Antonio ; Franzone, Anna ; Bedogni, Francesco ; Castriota, Fausto ; Attisano, Tiziana ; Søndergaard, Lars ; Antolin, Rosana Hernandez ; Tarantini, Giuseppe
  • Subjects: Acurate Neo ; Native aortic valve regurgitation ; Original Paper ; Transcatheter aortic valve replacement
  • Is Part Of: International journal of cardiology. Heart & vasculature, 2020-04, Vol.27, p.100480-100480, Article 100480
  • Description: •Native aortic valve regurgitation (NAVR) presents technical challenges for TAVR.•This is the largest study on NAVR patients treated with the ACURATE neo valve.•Intraprocedural mortality was 0%, device success 87.5% and moderate PVL rate 8.3%.•Device success tended to be higher with perimeter-based >10% oversizing. Transcatheter aortic valve replacement (TAVR) has been validated for the treatment of severe symptomatic aortic stenosis in patients at high and intermediate surgical risk. Recently, TAVR has been proposed as an alternative to medical therapy in inoperable patients with severe native aortic valve regurgitation (NAVR). This multicenter international registry sought to evaluate safety and efficacy of TAVR with the self-expandable ACURATE neo valve in a cohort of patients with NAVR. A total of 24 patients with severe NAVR treated by TAVR between September 2016 and October 2018 in 13 European centers were included. Clinical, procedural and follow up data were inserted in a dedicated database. Outcomes were codified according to Valve Academic Research Consortium-2 criteria. Mean age was 79.4 years, 58.4% were female. Mean EuroSCORE II and STS score were 5% and 3.9%, respectively. Device success was 87.5%. Moderate paravalvular leak (PVL) was found in two (8.3%) of patients, both with a perimeter oversizing index <10%. Implantation of a second device was necessary in three cases (12.5%), one for severe PVL and two for device displacement. New pacemaker implantation rate was 21.1%. At 30 days, stroke and all-cause mortality rates were 0% and 4.1%, respectively. This multicenter study suggests good feasibility and early safety of transfemoral TAVR with the self-expandable ACURATE neo device in patients with severe NAVR refused for surgery. Rates of moderate PVL, new pacemaker implantation and need for a second valve were higher than those reported for TAVR in aortic stenosis.
  • Publisher: Ireland: Elsevier B.V
  • Language: English
  • Identifier: ISSN: 2352-9067
    EISSN: 2352-9067
    DOI: 10.1016/j.ijcha.2020.100480
    PMID: 32083165
  • Source: PubMed Central
    ROAD: Directory of Open Access Scholarly Resources
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait